Download now: Gold and Silver Mining Stocks

Promising Biotech Startup

Merck (NYSE: MRK) to Invest $600 Million

Written by Swagato Chakravorty
Posted February 15, 2013 at 6:51PM

Some two years back, biotech giant Merck (NYSE: MRK) found a small startup’s work highly interesting. It paid the company—Lycera, a biotech from the University of Michigan—$12 million right away, with a further $295 million due, contingent on developmental milestones.

Tuesday, Lycera disclosed that Merck has in fact raised that package to $600 million, Fierce Biotech reports

Lycera works to attack autoimmune diseases, focusing on small molecules that target T-helper 17 (Th17) cells. The startup believes that this represents a novel approach toward combating several common autoimmune problems—rheumatoid arthritis, psoriasis, multiple sclerosis, and even inflammatory bowel disease.

Neither Merck nor Lycera have disclosed the details of this revamped funding package. However, according to Fierce Biotech, discovery deals typically comprise a smaller down payment with a much larger payment held in waiting, pending development and progress.

At the very least, the upgraded investment signals Merck’s intense interest in the biotech startup's work, as well as the perceived importance thereof.

Lycera received $36 million in a Series A financing round in 2009, and the company hopes to bring its candidate to clinic within the next year or year and a half.

The foundation of the company is CSO Gary Glick’s work at the University of Michigan, which led to the hypothesis that inhibiting retinoic acid related orphan receptor (RORyt) can lead to controlling IL-17.  


Related Articles

Canadian Biotech Receives Regulatory Approval
Kane Biotech (CVE: KNE) has received approval for its product to remove microbial biofilms that can cause chronic infections...
2012 Biotech Boom
This year has been great for the biotech industry, but it may have been pushed by a slump in pharmaceutical companies.
Biotech Collaborates with Startup on Cancer Drug
Major biotech Amgen (NASDAQ: AMGN) is working with a startup to create a drug targeting cancer cells.


What is the benefit of the email subscription?
While the Wealth Daily website offers access to the articles and reports, as a newsletter subscriber you will be among the first to receive access to the valuable advice, delivered directly to your inbox daily, and you will have access to deals on our exclusive services.
Who Owns Most of the World's Gold?
4% of the World Controls 12.6% of the Gold
Volkswagen: The Dumbest Car Company on the Planet
Will Volkswagen Expedite the Demise of the Internal Combustion Engine?
Organic Farmland Investing
Marc Faber and the Millionaire Farmer
Marijuana Legalization and the Case for Liberty
The Case for Cannabis Legalization
The World's Biggest Cash Crop